FDA Gives Accelerated Approval to Pirtobrutinib in CLL/SLL
Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma can now receive treatment with pirtobrutinib.
Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment
Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.
FDA Grants Priority Review for Pembrolizumab Combo in Bladder Cancer
The FDA accepts the supplemental biologics license application for enfortumab vedotin-ejfv and pembrolizumab in patients with urothelial cancer following supporting data from the phase 3 KEYNOTE-A39 trial.
Multidisciplinary Care and New Treatment Options in CRC
New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.
CAR T-cell Therapy Remains Preferred Options for Relapsed/Refractory Multiple Myeloma
Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.
Durvalumab/Tremelimumab/Surgery Appears Safe in Renal Cell Carcinoma
Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD, PhD.
2 Clarke Drive Cranbury, NJ 08512